Intellectual Property
HTG has intellectual properties associated with four advanced and innovative technologies including:
- Universal Arrays
- Quantitative Nuclease Protection Assay (qNPA™)
- Array printing
- Hybridization acceleration
Microarrays have transformed pharmaceutical research and development and life science research by allowing scientists to measure many different molecules in a single sample simultaneously.
Yet, while high-density microarrays have been valuable in identifying potential gene targets, their imprecision, cost, and the lack of consistency between the microarrays available from different vendors have limited their use for other aspects of drug discovery and diagnostics.
HTG’s ArrayPlate™ product is based on Universal Array IP, a technology that provides scientists, researchers and technicians with the flexibility to customize an ArrayPlate on the bench top using a simple reagent-addition protocol to measure a unique set of targets.
HTG technology combines the Universal Array with its quantitative Nuclease Protection Assay (qNPA) to provide clients with a breakthrough quantitative gene expression platform. The ArrayPlate product, based on these two technologies, delivers the Universal Array’s flexibility and qNPA’s excellent sensitivity, quantitative accuracy, precision and multiplexed, high-sample throughput to significantly enhance gene expression measurement.
